Annexon Biosciences, a biopharmaceutical company pioneering the development of classical complement pathway inhibitors to treat neurodegenerative disorders, today announced that FierceBiotech has named it to the 2016 Fierce 15 list of the most promising private biotechnology companies in the industry.
“All of us on the Annexon team are honored to be recognized among this year’s Fierce 15 companies,” said Doug Love, Esq., Chief Executive Officer and President of Annexon. “We have worked to rapidly translate our groundbreaking science into innovative, therapeutic candidates targeting C1q and the classical complement pathway. Our aim is to inhibit the neurodegenerative process in diseases such as Alzheimer’s, Huntington’s and glaucoma, and we are excited about the promise this novel therapeutic approach may hold for patients with these debilitating diseases. We look forward to beginning clinical trials in 2017 for our first in-class antibodies, ANX005 and ANX007.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fourteenth annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
Annexon Biosciences is pioneering the development of first-in-class therapeutic products that halt the progression of complement-mediated neurodegeneration (CMND). Backed by a team of experts in CMND, Annexon’s mission is to rapidly advance disease-modifying therapies for patients with acute and chronic neurodegenerative disorders. Annexon’s antibody pipeline is based on breakthrough research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in the loss of nerve connections, inflammation, and neuronal death. For more information, visit www.annexonbio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005771/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.